期刊文献+

2种常用肺炎克雷伯菌碳青霉烯类抗菌药物敏感性试验卡性能评价 被引量:1

Performance evaluation of GN13 and NM38 to determine the drug susceptibility of carbapenems against Klebsiella pneumoniae
下载PDF
导出
摘要 目的评价2种常用全自动微生物鉴定系统配套药物敏感性试验卡(GN13、NM38)检测肺炎克雷伯菌对碳青霉烯类抗菌药物敏感性的可靠性。方法收集2016年1月—2017年8月黄山市人民医院分离自临床样本的168株肺炎克雷伯菌,分别采用GN13、 NM38及微量肉汤稀释法测定其对碳青霉烯类抗菌药物的敏感性。以微量肉汤稀释法为金标准,对GN13和NM38的检测结果进行分析。采用改良碳青霉烯类灭活试验(mCIM)检测碳青霉烯酶,分析经仪器高级专家系统(AES)推测或预警提示为产碳青霉烯酶的可靠性。结果以微量肉汤稀释法为金标准, GN13与NM38检测结果的分类一致率(CA)均>90%。检测结果经AES修正后,GN13对亚胺培南的一般错误(MIE)和重大错误(ME)均降低了0.6%,对厄他培南的MIE增加了0.6%,均未出现严重错误(VME); NM38对亚胺培南的MIE、ME、VME分别为1.19%、1.19%、2.97%,对厄他培南的MIE、ME、VME分别为3.6%、0.0%、0.6%。mCIM表型检测结果显示碳青霉烯酶阳性率为27.4%(46/168),经AES修正后GN13推测和NM38预测产碳青霉烯酶的阳性率分别为31.0%和30.4%,与mCIM一致(P>0.05)。结论 GN13与NM38检测肺炎克雷伯菌对碳青霉烯类抗菌药物的性能均可靠,但应重视AES的修正或预警作用。 Objective To evaluate the reliabilities of VITEK 2-Compact GN13 and MicroScan WalkAway 96 Plus NM38 to determine the drug susceptibility of carbapenems against Klebsiella pneumoniae.Methods GN13,NM38 and broth micro-dilution method were used to determine the drug susceptibility of carbapenems to 168 isolates of Klebsiella pneumoniae which were isolated from Huangshan People's Hospital from January 2016 to August 2017.The determination results of GN13 and NM38 were judged by broth micro-dilution method as gold standard.A modified carbapenem inactivation method(mCIM)was used to determine carbapenems and to analyze their reliabilities of advanced expert system(AES)as a predictor or early warning indicator for carbapenem production.Results Using broth micro-dilution method as gold standard,GN13 and NM38 classification categorical agreement(CA)was>90%.Minor errors(MIE)and major errors(ME)for imipenem were reduced by 0.6%,and MIE for ertapenem was increased by 0.6%without very major errors(VME)after AES modification.The MIE,ME and VME determined by NM38 for imipenem accounted for 1.19%,1.19%and 2.97%,and MIE,ME and VME for ertapenem accounted for 3.6%,0.0%and 0.6%.The mCIM phenotype determination showed that the positive rate of carbapenems was 27.4%(46/168),and the positive rates of carbapenems after GN13 AES modification and NM38 prediction were 31.0%and 30.4%,respectively.Compared with mCIM,there was no statistical significance(P>0.05).Conclusions The results of GN13 and NM38 are reliable in determining the drug susceptibility of carbapenems against Klebsiella pneumoniae.However,attention should be paid to the modification or early warning of AES.
作者 张保华 余桂香 江燕 潘泓 蒋翔宁 ZHANG Baohua;YU Guixiang;JIANG Yan;PAN Hong;JIANG Xiangning(Department of Clinical Laboratory,Huangshan People's Hospital,Huangshan 245000,Anhui,China)
出处 《检验医学》 CAS 2019年第3期263-266,共4页 Laboratory Medicine
关键词 肺炎克雷伯菌 碳青霉烯酶 药物敏感性 CN13 NM38 Klebsiella pneumoniae Carbapenems Drug susceptibility GN13 NM38
  • 相关文献

参考文献3

二级参考文献23

  • 1王辉,刘颖梅,王清涛,孙宏莉,陈民钧.北京发现同时产DHA-1质粒AmpC型及CTX-M型超广谱β-内酰胺酶的肺炎克雷伯菌[J].中华微生物学和免疫学杂志,2005,25(5):419-422. 被引量:38
  • 2杨启文,徐英春,王辉,谢秀丽,陈民钧.CTX-M酶在北京协和医院临床分离大肠埃希菌中的流行[J].中国感染与化疗杂志,2006,6(1):1-6. 被引量:23
  • 3Clinical and Laboratory Standard Institute. M100-S23 Performance standards for antimicrobial susceptibility testing; twenty-third in- formational supplement[ S]. CLSI document M100-S23. Wayne, PA: CLSI, 2013.
  • 4Clinical and Laboratory Standard Institute. M02-A11 Performance standards for antimicrobial disk susceptibility tests; approved standard-eleventh edition [ S ]. CLSI document. Wayne, PA : CLSI, 2012.
  • 5Clinical and Laboratory Standard Institute. M07-A9 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aer- obically; approved standard-ninth edition [ S ]. Wayne, PA: CI2SI, 2012.
  • 6Tatman-Otkun M, GUrcan S, Ozer B, et al. The antimierobial susceptibility of Stenotrophomonas maltophilia isolates using three different methods and their genetic relatedness [ J ]. BMC Microbi- ol, 2005, 5: 24.
  • 7Kuper KM, Boles DM, Mohr JF, et al. Antimierobial susceptibili- ty testing: a primer for clinicians [ J ]. Pharmaeotherapy, 2009, 29( 11 ) : 1326-1343.
  • 8Jorgensen JH. Selection criteria for an antimicrobial susceptibility testing, svstem[J]. J Clin Mierobiol. 1993.31 ( 11 ) : 2841-2844.
  • 9Clinical and Laboratory Standard Institute. M100-S22 Performance standards for antimicrobial susceptibility testing; 22nd information- al supplement[S]. Wayne, PA: CLSI, 2012.
  • 10Bemer P, Juvin ME, Le Gargasson G, et al. Correlation between the VITEK2 system and cefoxitin disk diffusion for the daily detec- tion of oxacillin resistance in a large number of clinical Staphylo- coccus aureus isolates[ J]. Eur J Clin Microbial Infect Dis, 2010, 29 (6) : 745-747.

共引文献14

同被引文献3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部